The number of COVID-19 vaccination doses administered in the United Kingdom rose to 151248820 as of Oct 27 2023. This dataset includes a chart with historical data for the United Kingdom Coronavirus Vaccination Total.

Age-standardised mortality rates for deaths involving coronavirus (COVID-19), non-COVID-19 deaths and all deaths by vaccination status, broken down by age group.

Covid vaccinations administered by local area since 8th December 2020. It includes the calculated percentage of the 12+ population who have received all required vaccinations and/or boosters.Population estimates are based on National Immunisation Management Service counts.

Information on number of COVID vaccinations and payments made to individual branches listed by their ODS code in the same format as FOI 19177: https://opendata.nhsbsa.net/dataset/foi-19177 Can I get an historical extract going back to when the vaccinations first began. Would you also be able to provide this data on an ongoing monthly basis when new data is made available? Response A copy of the information is attached. Regarding your query about making the data available on an on-going basis, there is no current plan to routinely publish this information. Therefore please continue to request the information at regular intervals if you wish to receive this regularly. The NHSBSA makes payments for covid vaccinations to Pharmacies and Primary Care Network (PCN) providers in England. Covid vaccination data is keyed in via Point of Care (POC) Systems and they transferred to the NHSBSA Manage Your Service (MYS) application. Each month, vaccine providers submit claims to request payment based on the data that has been transferred into MYS. To be paid in a timely fashion such claims must be submitted during a specified declaration submission period. Should claims be submitted outside the time windows, payments will be made later. This means that in some cases there is a difference between the number of vaccines that have been 'claimed' and the number that have been 'paid'. Both the number of 'claimed' and 'paid' vaccinations have been reported in this request. When considering the nature of the vaccine data there are several ways it can be reported over time: Administration Month - This is the month in which the vaccine was administered to the patient. Payment Month - This is the month in which the payment was made dispenser of the vaccine. Note that all payments for Pharmacies are paid one month later than those for PCN providers. Keying Month - This is the month in which the vaccine record first appeared on the MYS system. Submission/Claim Month - This is the month in which the claim for payment for a vaccination occurred. For example, suppose that a PCN patient is given a covid vaccination dose 1 in January (Administration Month) and then the paper record of this is misplaced for a while. The record is found and keyed into a POC system during February (Keying Month). The Provider is allowed to claim for keying during February in the first 5 days of March, but they're a little late and authorise the claim on the 7th of March (Submission Month) As the claim is outside the submission window it is not paid in March, it will instead be paid during April (Payment Month). Another example could be a Pharmacy patient given a covid vaccination dose 1 in January (Administration Month), keyed in January (Keying Month), then submitted in February (Submission Month) and then payments are calculated in February, however as this is for a pharmacy the payments are held back and not paid until March (Payment Month). For the purposes of this request, we have chosen to report by Administration Month. Data included in this request is limited to vaccinations carried out by Pharmacies only. The latest data used is a snapshot of the MYS system data that was taken on 7th January 2022. This is the snapshot of data taken after the January submission period that was used to calculate payments The total used for the payment calculation may not match the totals shown in 'live' POC systems or MYS that continue to receive updates after the snapshot used to calculate payments was taken. Vaccination records are limited to those which have been associated with a declaration submission. This may include late submission declarations received after the deadline for declarations such records are not processed until the next month. Please note that some vaccinations attract a supplementary fee, so it is not possible to determine the number of vaccinations by dividing the total paid by the basic Item of Service (IoS) fee. It is possible for new records from old administration months to be entered in the future, thus the totals here for each administration months could change when more data is processed. If you have any queries regarding the data provided, or if you plan on publishing the data, please contact dataandinsightsupport@nhsbsa.nhs.uk ensuring you quote the above reference. This is important to ensure that the figures are not misunderstood or misrepresented. If you plan on producing a press or broadcast story based upon the data please contact nhsbsa.communicationsteam@nhs.net. This is important to ensure that the figures are not misunderstood or misrepresented.

Flu vaccine uptake (%) in adults aged 65 and over, who received the flu vaccination between 1st September to the end of February as recorded in the GP record. The February collection has been adopted for our end of season figures from 2017 to 2018. All previous data is the same definitions but until the end of January rather than February to consider data returning from outside the practice and later in practice vaccinations.RationaleInfluenza (also known as Flu) is a highly infectious viral illness spread by droplet infection. The flu vaccination is offered to people who are at greater risk of developing serious complications if they catch the flu. The seasonal influenza programme for England is set out in the Annual Flu Letter. Both the flu letter and the flu plan have the support of the Chief Medical Officer (CMO), Chief Pharmaceutical Officer (CPhO), and Director of Nursing.Vaccination coverage is the best indicator of the level of protection a population will have against vaccine-preventable communicable diseases. Immunisation is one of the most effective healthcare interventions available, and flu vaccines can prevent illness and hospital admissions among these groups of people. Increasing the uptake of the flu vaccine among these high-risk groups should also contribute to easing winter pressure on primary care services and hospital admissions. Coverage is closely related to levels of disease. Monitoring coverage identifies possible drops in immunity before levels of disease rise.The UK Health Security Agency (UKHSA) will continue to provide expert advice and monitoring of public health, including immunisation. NHS England now has responsibility for commissioning the flu programme, and GPs continue to play a key role. NHS England teams will ensure that robust plans are in place locally and that high vaccination uptake levels are reached in the clinical risk groups. For more information, see the Green Book chapter 19 on Influenza.The Annual Flu Letter sets out the national vaccine uptake ambitions each year. In 2021 to 2022, the national ambition was to achieve at least 85 percent vaccine uptake in those aged 65 and over. Prior to this, the national vaccine uptake ambition was 75 percent, in line with WHO targets.Definition of numeratorNumerator is the number of vaccinations administered during the influenza season between 1st September and the end of February.Definition of denominatorDenominator is the GP registered population on the date of extraction including patients who have been offered the vaccine but refused it, as the uptake rate is measured against the overall eligible population. For more detailed information please see the user guide, available to view and download from https://www.gov.uk/government/collections/vaccine-uptake#seasonal-flu-vaccine-uptakeCaveatsRead codes are primarily used for data collection purposes to extract vaccine uptake data for patients who fall into one or more of the designated clinical risk groups. The codes identify individuals at risk, and therefore eligible for flu vaccination. However, it is important to note that there may be some individuals with conditions not specified in the recommended risk groups for vaccination, who may be offered influenza vaccine by their GP based on clinical judgement and according to advice contained in the flu letter and Green Book, and thus are likely to fall outside the listed Read codes. Therefore, this data should not be used for GP payment purposes.

Thank you for your request for information about the following: Please provide the number of COVID vaccinations provided EACH month for the following pharmacy based in England. FVW12 - Hughenden Valley Pharmacy, HIGH WYCOMBE, HP14 4LG. Please provide monthly breakdown for NOVEMBER 2021, DECEMBER 2021, JANUARY 2022, FEBRUARY 2022 & MARCH 2022 Your request was received on 11 August 2023 and has been dealt with under the terms of the Freedom of Information Act 2000. Response A copy of the information is attached. Please note that pharmacies only need to tell us about the vaccines that they administer if they want to be paid for them - so strictly our data is about payments for vaccines rather than the vaccines themselves The NHSBSA calculates payments for covid vaccinations to Pharmacies and Primary Care Network (PCN) providers in England. Covid vaccination data is keyed in via Point of Care (POC) Systems and they transferred to the NHSBSA Manage Your Service (MYS) application. Each month, vaccine providers submit claims to request payment based on the data that has been transferred into MYS. To be paid in a timely fashion such claims must be submitted during a specified declaration submission period. Should claims be submitted outside the submission period they will be processed in the following period. This means that in some cases there is a difference between the number of vaccines that have been 'claimed' and the number that have been 'paid'. Only 'paid' vaccinations have been reported in this request. When considering the nature of the vaccine data there are several ways it can be reported over time: Administration Month: This is the month in which the vaccine was administered to the patient. Payment Month: This is the month in which the payment was made dispenser of the vaccine. Note that all payments for Pharmacies are paid one month later than those for PCN providers. Keying Month: This is the month in which the vaccine record first appeared on the MYS system. Submission/Claim Month: This is the month in which the claim for payment for a vaccination occurred. For example, suppose that a PCN patient is given a covid vaccination dose 1 in January (Administration Month) and then the paper record of this is misplaced for a while. The record is found and keyed into a POC system during February (Keying Month). The Provider is allowed to claim for keying during February in the first 5 days of March, but they're a little late and authorise the claim on the 7th of March (Submission Month). As the claim is outside the submission window it is not paid in March, it will instead be processed during April (Payment Month). Another example could be a Pharmacy patient given a covid vaccination dose 1 in January (Administration Month), keyed in January (Keying Month), then submitted in February (Submission Month) and then payments are calculated in February, however as this is for a pharmacy the payments are held back and not paid until March (Payment Month). For the purposes of this request, we have chosen to report by Administration Month. Data included in this request is limited to vaccinations carried out by FVW12 - Hughenden Valley Pharmacy, HIGH WYCOMBE, HP14 4LG only. Data included in this request is also limited to vaccinations administered between November 2021 and March 2022. The latest data used is a snapshot of the MYS system data that was taken on 7th August 2023. This is the snapshot of data taken after the July 2023 submission period that was used to calculate payments. Pharmacy name and address are as held at this date. Vaccination records are limited to those which have been associated with a declaration submission. This may include late submission declarations received after the deadline for declarations such records are not processed until the next month.

Includes: Patient demographics, Source Organisation, Adverse reaction details. Its scope covers: Anyone vaccinated within England and anyone vaccinated in a Devoted Administration where this information is subsequently passed to England.

Settings include hospital hubs - NHS providers vaccinating on site local vaccine services – community or primary care led services which could include primary care facilities, retail, community facilities, temporary structures or roving teams vaccination centres – large sites such as sports and conference venues set up for high volumes of people

Timescales for dissemination can be found under 'Our Service Levels' at the following link: https://digital.nhs.uk/services/data-access-request-service-dars/data-access-request-service-dars-process

The information in this bulletin about immunisation statistics in England comes from Public Health England (PHE). Information on childhood immunisation coverage at ages 1, 2 and 5 years is collected through the Cover of Vaccination Evaluated Rapidly (COVER) data collection for Upper Tier Local Authorities (LAs) and Primary Care Trusts (PCTs). Information on persons aged 65 and over immunised against seasonal flu is collected from GPs through PHE's ImmForm system. 3rd November 2014: Subsequent to publishing on 25 September 2014, an error was identified where Rutland Local Authority (LA) was incorrectly merged with Leicester LA instead of Leicestershire LA. England and regional level figures are not affected but some of the coverage figures for Leicestershire and Leicester are. The HSCIC apologises for the inconvenience caused by this error and has reissued the figures for Leicester and Leicestershire in Tables 10a, 10b, 11a, 11b, 12a, 12b in the Excel and CSV files. The PDF report has also been revised.

IntroductionGuidelines for the management of rheumatoid arthritis (RA) recommend using influenza and pneumococcal vaccinations to mitigate infection risk. The level of adherence to these guidelines is not well known in the UK. The aims of this study were to describe the uptake of influenza and pneumococcal vaccinations in patients with RA in the UK, to compare the characteristics of those vaccinated to those not vaccinated and to compare vaccination rates across regions of the UK.MethodsA retrospective cohort study of adults diagnosed with incident RA and treated with non-biologic immunosuppressive therapy, using data from a large primary care database. For the influenza vaccination, patients were considered unvaccinated on 1st September each year and upon vaccination their status changed to vaccinated. For pneumococcal vaccination, patients were considered vaccinated after their first vaccination until the end of follow-up. Patients were stratified by age 65 at the start of follow-up, given differences in vaccination guidelines for the general population.ResultsOverall (N = 15,724), 80% patients received at least one influenza vaccination, and 50% patients received a pneumococcal vaccination, during follow-up (mean 5.3 years). Of those aged below 65 years (N = 9,969), 73% patients had received at least one influenza vaccination, and 43% patients received at least one pneumococcal vaccination. Of those aged over 65 years (N = 5,755), 91% patients received at least one influenza vaccination, and 61% patients had received at least one pneumococcal vaccination. Those vaccinated were older, had more comorbidity and visited the GP more often. Regional differences in vaccination rates were seen with the highest rates in Northern Ireland, and the lowest rates in London.ConclusionsOne in five patients received no influenza vaccinations and one in two patients received no pneumonia vaccine over five years of follow-up. There remains significant scope to improve uptake of vaccinations in patients with RA.

All children at age 12 months who have received the complete course (3 doses) of hepatitis B vaccine within each reporting area as a percentage of all the eligible population as defined in the hepatitis B chapter of the immunisation against infectious diseases "Green Book" (have maternal Hep B positive status).RationaleInfants born to hepatitis B virus (HBV) infected mothers are at high risk of acquiring HBV infection themselves. Babies born to infected mothers are given a dose of the hepatitis B vaccine after they are born. This is followed by another two doses (with a month in between each) and a booster dose 12 months later. Around 20% of people with chronic hepatitis B will go on to develop scarring of the liver (cirrhosis), which can take 20 years to develop, and around 1 in 10 people with cirrhosis will develop liver cancer.Vaccination coverage is the best indicator of the level of protection a population will have against vaccine preventable communicable diseases. Coverage is closely correlated with levels of disease. Monitoring coverage identifies possible drops in immunity before levels of disease rise.Since April 2000 it has been recommended that all pregnant women in England and Wales should be offered testing for hepatitis B through screening for HBsAg, and that all babies of HBsAg seropositive women should be immunised (HSC 1998 127). A dose of paediatric hepatitis B vaccine is recommended for all infants born to an HBV infected mother as soon as possible after birth, then at 1 and 2, and 12 months of age ( https://www.gov.uk/government/collections/hepatitis-b-guidance-data-and-analysis ). Previous evidence shows that highlighting vaccination programmes encourages improvements in uptake levels may also have relevance for NICE guidance PH21: Reducing differences in the uptake of immunisations (The guidance aims to increase immunisation uptake among those aged under 19 years from groups where uptake is low).Definition of numeratorNumber of children at age 12 months who have received the complete course (3 doses) of hepatitis B vaccine. Numerator counts for local authorities include all people registered with practices in the local authority, and no data are available to provide resident based figures.Definition of denominatorEligible population as defined in the hepatitis B chapter of the immunisation against infectious diseases "Green Book" (have maternal Hep B positive status).Denominators for local authorities include all people registered with practices in the local authority, and no data are available to provide resident based figures.CaveatsThese statistics have been published as ‘experimental statistics’ in the NHS Digital “NHS Immunisation Statistics, England” report. There are a number of issues with the hepatitis B dataset which have either impacted on data quality or have raised potential concerns around the quality of the data. Selective neonatal hepatitis B coverage data are reported by local authority (LA) responsible population for the first time in the 2015 to 2016 publication. Many LAs could not supply complete data on infants born to hepatitis B positive mothers and for a number of other LAs there were data quality issues. It has therefore not been possible to estimate figures for those LAs or describe the quality/completeness of LA data with any accuracy. (see Quality Statement for 2015 to 2016 for more information). Office of Health Improvement and Disparities has also published data for LAs that are co terminus with former PCTs but provided data by PCT rather than LA. These data were not published or validated by NHS Digital.

Main determinants of shingles vaccination.

As of May 2, 2023, there were roughly 687 million global cases of COVID-19. Around 660 million people had recovered from the disease, while there had been almost 6.87 million deaths. The United States, India, and Brazil have been among the countries hardest hit by the pandemic.

The various types of human coronavirus The SARS-CoV-2 virus is the seventh known coronavirus to infect humans. Its emergence makes it the third in recent years to cause widespread infectious disease following the viruses responsible for SARS and MERS. A continual problem is that viruses naturally mutate as they attempt to survive. Notable new variants of SARS-CoV-2 were first identified in the UK, South Africa, and Brazil. Variants are of particular interest because they are associated with increased transmission.

Vaccination campaigns Common human coronaviruses typically cause mild symptoms such as a cough or a cold, but the novel coronavirus SARS-CoV-2 has led to more severe respiratory illnesses and deaths worldwide. Several COVID-19 vaccines have now been approved and are being used around the world.

Responders and non-responders characteristics.

Erysipelas, caused by the bacterium Erysipelothrix rhusiopathiae, is re-emerging in swine and poultry production systems worldwide. While the global genomic diversity of this species has been characterized, how much of this genomic and functional diversity is maintained at smaller scales is unclear. Specifically, while several key immunogenic surface proteins have been identified for E. rhusiopathiae, little is known about their presence among field strains and their divergence from vaccines, which could result in vaccine failure. Here, a comparative genomics approach was taken to determine the diversity of E. rhusiopathiae strains in pigs in Great Britain over nearly three decades, as well as to assess the field strains’ divergence from the vaccine strain most commonly used in British pigs. In addition, the presence/absence and variability of 13 previously described immunogenic surface proteins was determined, including SpaA which is considered a key immunogen. We found a high diversity of E. rhusiopathiae strains in British pigs, similar to the situation described in European poultry but in contrast to swine production systems in Asia. Of the four clades of E. rhusiopathiae found globally, three were represented among British pig isolates, with Clade 2 being the most common. All British pig isolates had one amino acid difference in the immunoprotective domain of the SpaA protein compared to the vaccine strain. However, we were able to confirm using in silico structural protein analyses that this difference is unlikely to compromise vaccine protection. Of 12 other known immunogenic surface proteins of E. rhusiopathiae examined, 11 were found to be present in all British pig isolates and the vaccine strain, but with highly variable degrees of conservation at the amino acid sequence level, ranging from 0.3 to 27% variant positions. Moreover, the phylogenetic incongruence of these proteins suggests that horizontal transfer of genes encoding for antigens is commonplace for this bacterium. We hypothesize that the sequence variants in these proteins could be responsible for differences in the efficacy of the immune response. Our results provide the necessary basis for testing this hypothesis through in vitro and in vivo studies.